Literature DB >> 8945697

Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? Characteristics of materials distributed by drug companies: four points of view.

S M Wolfe.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  1996        PMID： 8945697     DOI： 10.1007/bf02599033

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  7 in total

1.  Addressing the problem of misleading advertising.

Authors:  D A Kessler
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

2.  Pharmaceutical advertisements in leading medical journals: experts' assessments.

Authors:  M S Wilkes; B H Doblin; M F Shapiro
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

3.  Drug advertisements that go straight to the hippocampus.

Authors:  S Wolfe
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

Review 4.  Characteristics of materials distributed by drug companies. An evaluation of appropriateness.

Authors:  D Stryer; L A Bero
Journal:  J Gen Intern Med       Date:  1996-10       Impact factor: 5.128

Review 5.  Trends in pharmacologic management of hypertension in the United States.

Authors:  T A Manolio; J A Cutler; C D Furberg; B M Psaty; P K Whelton; W B Applegate
Journal:  Arch Intern Med       Date:  1995-04-24

Review 6.  Pharmacotherapy of the depressed patient with cardiovascular and/or cerebrovascular illness.

Authors:  R M Lane; M Sweeney; J A Henry
Journal:  Br J Clin Pract       Date:  1994 Sep-Oct

Review 7.  Patient pack prescribing and the provision of patient information leaflets.

Authors: 
Journal:  Drug Ther Bull       Date:  1995-11
  7 in total
  10 in total

1.  Pharmaceutical advertising revenue and physician organizations: how much is too much?

Authors:  P A Glassman; J Hunter-Hayes; T Nakamura
Journal:  West J Med       Date:  1999-10

2.  Direct to consumer advertising of prescription drugs. An idea whose time should not come.

Authors:  J R Hoffman; M Wilkes
Journal:  BMJ       Date:  1999-05-15

3.  [Psychiatrists and the pharmaceutical industry].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

4.  The relationship between physicians and the pharmaceutical industry: ethical problems with the every-day conflict of interest.

Authors:  Richard L Allman
Journal:  HEC Forum       Date:  2003-06

5.  The future sponsorship of CME in Canada: industry, government, physicians or a blend?

Authors:  Bernard Marlow
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

6.  Drug companies and information about drugs: recommendations for doctors. Characteristics of materials distributed by drug companies: four points of view.

Authors:  C S Landefeld; M M Chren
Journal:  J Gen Intern Med       Date:  1996-10       Impact factor: 5.128

7.  A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts.

Authors:  R V Gibbons; F J Landry; D L Blouch; D L Jones; F K Williams; C R Lucey; K Kroenke
Journal:  J Gen Intern Med       Date:  1998-03       Impact factor: 5.128

8.  Should physicians rely on pharmaceutical detailing for their education?

Authors:  Johan M van Schalkwyk; Martin J Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-12-14       Impact factor: 3.738

9.  A survey of pharmaceutical company representative interactions with doctors in Libya.

Authors:  Mustafa A Alssageer; Stefan R Kowalski
Journal:  Libyan J Med       Date:  2012-09-18       Impact factor: 1.657

Review 10.  Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.

Authors:  Freek Fickweiler; Ward Fickweiler; Ewout Urbach
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.